Table 2 Treatment emergent adverse events (TEAE) occurring in >10% of patients receiving P-BCMA-ALLO1
TEAE, n (%) (N = 34) | All Grades | Grade ≥ 3 | Treatment-related Grade ≥ 3 |
|---|---|---|---|
Anemia | 12 (35.3) | 9 (26.5) | 7 (20.6) |
Neutropenia | 11 (32.4) | 11 (32.4) | 9 (26.5) |
Leukopenia | 10 (29.4) | 10 (29.4) | 8 (23.5) |
Arthralgia | 8 (23.5) | 0 ((0) | 0 (0) |
Constipation | 8 (23.5) | 0 (0) | 0 (0) |
Diarrhea | 8 (23.5) | 0 (0) | 0 (0) |
Fatigue | 8 (23.5) | 0 (0) | 0 (0) |
Thrombocytopenia | 8 (23.5) | 4 (11.8) | 1 (2.9) |
Cytokine release syndrome (CRS) | 7 (20.6) | 0 (0) | 0 (0) |
Headache | 7 (20.6) | 0 (0) | 0 (0) |
Hypokalemia | 7 (20.6) | 0 (0) | 0 (0) |
Febrile neutropenia | 5 (14.7) | 5 (14.7) | 3 (8.8) |
Insomnia | 5 (14.7) | 0 (0) | 0 (0) |
Nausea | 5 (14.7) | 0 (0) | 0 (0) |
Peripheral edema | 5 (14.7) | 0 (0) | 0 (0) |
Chills | 4 (11.8) | 1 (2.9) | 0 (0) |
Dizziness | 4 (11.8) | 0 (0) | 0 (0) |
Pyrexia | 4 (11.8) | 0 (0) | 0 (0) |
Hypertension | 4 (11.8) | 1 (2.9) | 0 (0) |
Hypophosphatemia | 4 (11.8) | 0 (0) | 0 (0) |
